WT1 and acute myeloid leukemia: ETC therapy targeting a WT1 peptide uses non-transduced, non-engineered WT1-specific CTLs that have been primed and expanded in vitro from rare populations of peripheral blood-derived WT1-specific T cells and epigenetically programmed into central memory T cells (Tcm), which can elicit long-lasting immune protection against relapse in patients with high-risk AML [12].